Keros Therapeutics (NASDAQ:KROS) announced the resignation of its Chief Medical Officer, Simon Cooper, M.B.B.S., effective March 12, 2024. Dr. Cooper is departing to pursue other opportunities. His decision to leave the company is voluntary and not due to any disagreements with Keros Therapeutics' policies or practices.
The biotechnology firm, which specializes in the development of treatments for hematological and musculoskeletal disorders, has begun the process of finding a replacement for Dr. Cooper. In the interim, his responsibilities will be managed by the existing medical team to ensure continuity of the company's clinical programs.
Dr. Cooper has been commended for his contributions to Keros Therapeutics, both as Chief Medical Officer and as a member of the executive team. The company expressed gratitude for his service and the role he played in advancing their medical initiatives.
This transition comes at a time when Keros Therapeutics continues to focus on its pipeline of innovative therapies. The company has not yet named a successor, but the search for a new Chief Medical Officer is underway.
The information reported is based on the latest SEC filing by Keros Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.